Batoclimab

Batoclimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting FCGRT, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Batoclimab (HBM9161) is a fully human antibody targeting the neonatal Fc receptor (FcRn). It targets patients with neuromyelitis optica spectrum diseases and other autoimmune diseases, and can accelerate the degradation of autoantibodies in their bodies. Batoclimab (HBM9161) is an antibody that targets the neonatal Fc receptor (FcRn). FcRn expression is up-regulated by pro-inflammatory cytokines (such as TNF-α) and prolongs the half-life of IgG and serum albumin by reducing lysosomal degradation in endothelial cells and bone marrow-derived cells. Blocking the FcRn-IgG interaction can accelerate the degradation of autoantibodies and reduce the onset of various pathogenic IgG-mediated autoimmune diseases, including myasthenia gravis, thyroid ophthalmopathy, neuromyelitis optica spectrum disease and immunity Thrombocytopenia.

Target	FCGRT
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA, WB
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1 Lambda
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer	0.01 M PBS. pH 7.4.
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 7-12 working days.
Note	This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.

Research Articles on FCGRT

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue